Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine + quizartinib versus venetoclax + azacitidine in newly diagnosed AML ineligible for intensive induction
2025-522979-29-00Phase 3Authorised
- Sponsor
- PETHEMA
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Quizartinib + venetoclax + azacitidine with Venetoclax + azacitidine (2 arms). Primary endpoint: Overall survival. Planned start Apr 2026; status: authorised.
02
Drugs
quizartinibvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-522979-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522979-29-00.